Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D. In addition, Peppi Prasit, Ph.D. leads the Scientific Advisory Board and Leonard Bell, M.D., serves as Chair of the Board of Directors. Its team of technology trailblazers and proven drug developers are driving the discovery and development of novel small molecule drugs to treat patients suffering with severe and debilitating diseases. The company expects to develop drug candidates both internally and selectively in partnership with biopharmaceutical companies. 

Biotechnology

Education

Genesis Therapeutics

Evan Feinberg

Senior Manager, Program And Alliance Management

Principal Infrastructure Engineer Lead

Dean Latney

Maruan Al-Shedivat

Principal QM Research Scientist / Engineer

Vyom Thakkar

Drake Diedrich

Zach Kagin

Bing Han

Wang Xu

Luis Landgrave

Louie Naumovski

Indrawan McAlpine

Matt Pan

Parvin Parineh

Peppi Prasit

Will McCarthy

The Biology & Chemistry Team at Genesis Therapeutics spearheads the discovery and optimization of novel small molecule drugs. Leveraging cutting-edge molecular AI technology, the team conducts rigorous biological and chemical research, including medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), and immunology. Their expertise is critical to advancing treatment options for severe and debilitating diseases, ensuring that drug candidates are scientifically validated and clinically promising.

Biology & Chemistry Team

Machine Learning and AI Team

Leadership Team

Biology & Chemistry Team

About

Team members

Other teams at Genesis Therapeutics

Machine Learning and AI Team

Leadership Team